Results 121 to 130 of about 868 (155)
Some of the next articles are maybe not open access.
Outcomes of Therasphere Radioembolization for Colorectal Metastases
Clinical Colorectal Cancer, 2015The liver is the most common site for colorectal cancer (CRC) metastases. Radioembolization with yttrium-90 (Y90) represents an alternative approach in the management of unresectable hepatic colorectal metastases. The objective of this study was to evaluate outcomes after treatment with Y90.A retrospective review of patients undergoing Y90 glass ...
Jonathan Strosberg +2 more
exaly +3 more sources
Journal of Vascular and Interventional Radiology, 2005
To present safety and efficacy results obtained in treatment of a cohort of patients with unresectable hepatocellular carcinoma (HCC) with use of 90Y microspheres (TheraSphere).Forty-three consecutive patients with HCC were treated with 90Y microspheres over a 4-year period.
Stuart C Gordon +2 more
exaly +3 more sources
To present safety and efficacy results obtained in treatment of a cohort of patients with unresectable hepatocellular carcinoma (HCC) with use of 90Y microspheres (TheraSphere).Forty-three consecutive patients with HCC were treated with 90Y microspheres over a 4-year period.
Stuart C Gordon +2 more
exaly +3 more sources
Journal of Vascular and Interventional Radiology, 2004
Intra-arterial injection of Yttrium-90 glass microspheres ((90)Y- microS; TheraSphere, MDS Nordion, Ottawa, Canada) is indicated for treatment of unresectable hepatocellular carcinoma (HCC) in the presence of acceptable liver function. This study presents hepatic toxicity results after unilobar and bilobar intra-arterial administration of (90)Y- microS
Riad Salem +2 more
exaly +3 more sources
Intra-arterial injection of Yttrium-90 glass microspheres ((90)Y- microS; TheraSphere, MDS Nordion, Ottawa, Canada) is indicated for treatment of unresectable hepatocellular carcinoma (HCC) in the presence of acceptable liver function. This study presents hepatic toxicity results after unilobar and bilobar intra-arterial administration of (90)Y- microS
Riad Salem +2 more
exaly +3 more sources
British Journal of Radiology
Abstract Objective Primary and secondary hepatic malignancies are a significant cause of cancer-related mortality worldwide. Radioembolization with yttrium-90 (90Y) microspheres has emerged as a promising treatment option for unresectable hepatic tumours.
Ashish Kumar Jha +2 more
exaly +3 more sources
Abstract Objective Primary and secondary hepatic malignancies are a significant cause of cancer-related mortality worldwide. Radioembolization with yttrium-90 (90Y) microspheres has emerged as a promising treatment option for unresectable hepatic tumours.
Ashish Kumar Jha +2 more
exaly +3 more sources
Health Physics, 2012
Yittrium-90 microsphere brachytherapy procedures have increased in number due to their efficacy in treating some unresectable metastatic liver tumors. The discovery of long-lived impurities in two microsphere products, first reported between 2006 and 2007, has resulted in some radiation safety concerns. Since then, microsphere production processes have
John Metyko
exaly +3 more sources
Yittrium-90 microsphere brachytherapy procedures have increased in number due to their efficacy in treating some unresectable metastatic liver tumors. The discovery of long-lived impurities in two microsphere products, first reported between 2006 and 2007, has resulted in some radiation safety concerns. Since then, microsphere production processes have
John Metyko
exaly +3 more sources
CardioVascular and Interventional Radiology, 2017
To compare the safety profiles of TheraSphere® (glass) and SIR-Spheres® (resin) Y90 microspheres for the treatment of hepatocellular carcinoma. A systematic review was conducted using the databases MEDLINE, Embase, and Cochrane Trials Register to identify all relevant studies.
Kristian Thorlund +2 more
exaly +3 more sources
To compare the safety profiles of TheraSphere® (glass) and SIR-Spheres® (resin) Y90 microspheres for the treatment of hepatocellular carcinoma. A systematic review was conducted using the databases MEDLINE, Embase, and Cochrane Trials Register to identify all relevant studies.
Kristian Thorlund +2 more
exaly +3 more sources
Journal of Vascular and Interventional Radiology, 2009
To evaluate the impact of identifiable hepatic vein tumor thrombus on the ability to safely deliver TheraSphere (yttrium 90-containing glass microspheres) for the treatment of hepatocellular carcinoma (HCC).A retrospective review was performed of 87 patients (71 men, 16 women; mean age, 64.5 years; age range, 25-83 y) referred for TheraSphere therapy ...
Lewis R. Roberts, James C Andrews
exaly +3 more sources
To evaluate the impact of identifiable hepatic vein tumor thrombus on the ability to safely deliver TheraSphere (yttrium 90-containing glass microspheres) for the treatment of hepatocellular carcinoma (HCC).A retrospective review was performed of 87 patients (71 men, 16 women; mean age, 64.5 years; age range, 25-83 y) referred for TheraSphere therapy ...
Lewis R. Roberts, James C Andrews
exaly +3 more sources
International Journal of Radiation Oncology*Biology*Physics, 2010 A.J. Ghia +4 more
openaire +2 more sources
American Journal of Surgical Pathology, 2019
Selective internal radiation therapy with 90Y-TheraSphere or 90Y-SIRSphere is used in the treatment of unresectable hepatic malignancies. To the best of our knowledge, this is the first 90Y-TheraSpheres series. BTG International Canada Inc. provided nonradiated microspheres from the Nordion manufacturer.
Christina A, Arnold +5 more
openaire +2 more sources
Selective internal radiation therapy with 90Y-TheraSphere or 90Y-SIRSphere is used in the treatment of unresectable hepatic malignancies. To the best of our knowledge, this is the first 90Y-TheraSpheres series. BTG International Canada Inc. provided nonradiated microspheres from the Nordion manufacturer.
Christina A, Arnold +5 more
openaire +2 more sources
Journal of Surgical Oncology, 2006
To present the clinical data of 35 patients with T3 unresectable hepatocellular carcinoma (HCC) that were treated with (90)Y with the specific intent of downstaging to resection, radiofrequency ablation (RFA) candidate, United Network for Organ Sharing (UNOS) stage T2 or liver transplantation.One hundred fifty patients with unresectable HCC were ...
Laura M, Kulik +10 more
openaire +2 more sources
To present the clinical data of 35 patients with T3 unresectable hepatocellular carcinoma (HCC) that were treated with (90)Y with the specific intent of downstaging to resection, radiofrequency ablation (RFA) candidate, United Network for Organ Sharing (UNOS) stage T2 or liver transplantation.One hundred fifty patients with unresectable HCC were ...
Laura M, Kulik +10 more
openaire +2 more sources